1. Optimization of cyclic sulfamide derivatives as 11β-hydroxysteroid dehydrogenase 1 inhibitors for the potential treatment of ischemic brain injury.
- Author
-
Lee JH, Bok JH, Park SB, Pagire HS, Na YJ, Rim E, Jung WH, Song JS, Kang NS, Seo HW, Jung KY, Lee BH, Kim KY, and Ahn JH
- Subjects
- 11-beta-Hydroxysteroid Dehydrogenase Type 1 metabolism, Amides metabolism, Animals, Brain metabolism, Brain Injuries drug therapy, Brain Injuries pathology, Cyclization, Enzyme Inhibitors metabolism, Enzyme Inhibitors therapeutic use, Humans, Infarction, Middle Cerebral Artery drug therapy, Infarction, Middle Cerebral Artery pathology, Injections, Intraperitoneal, Mice, Structure-Activity Relationship, 11-beta-Hydroxysteroid Dehydrogenase Type 1 antagonists & inhibitors, Amides chemistry, Enzyme Inhibitors chemistry
- Abstract
The 11β-hydroxysteroiddehydrogenase type 1(11β-HSD1), acortisolregenerating enzyme that amplifies tissue glucocorticoidlevels, plays an important role in diabetes, obesity, and glaucoma and is recognized as a potential therapeutic target for various disease conditions. Moreover, a recent study demonstrated that selective 11β-HSD1 inhibitor can attenuate ischemic brain injury. This prompted us to optimize cyclic sulfamide derivative for aiming to treat ischemic brain injury. Among the synthesized compounds, 6e has an excellent in vitro activivity with an IC
50 value of 1 nM toward human and mouse 11β-HSD1 and showed good 11β-HSD1 inhibition in ex vivo study using brain tissue isolated from mice. Furthermore, in the transient middle cerebral artery occlusion model in mice, 6e treatment significantly attenuated infarct volume and neurological deficit following cerebral ischemia/reperfusion injury. Additionally, binding modes of 6e for human and mouse 11β-HSD1 were suggested., (Copyright © 2019 Elsevier Ltd. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF